The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials
Abstract
BACKGROUND: A variety of antiarrhythmic drugs have been used to prevent recurrence of atrial fibrillation after conversion to sinus rhythm. We performed a systematic review to determine the effect of long-term treatment with those drugs on death, embolisms, adverse effects, and atrial fibrillation recurrence. METHODS: We searched MEDLINE, EMBASE, the Cochrane Library (all up to May 2005), and the reference lists of retrieved articles. We included randomized controlled trials that compared any antiarrhythmic against control (placebo or no treatment) or another antiarrhythmic, for more than 6 months. Postoperative atrial fibrillation was excluded. Two evaluators independently reviewed the retrieved studies and extracted all data. Disagreements were resolved by discussion. All results were calculated at 1 year of follow-up. RESULTS: Forty-four trials were included, with a total of 11 322 patients. Several class IA (disopyramide phosphate, quinidine sulfate), class IC (flecainide acetate, propafenone hydrochloride), and class III (amiodarone, dofetilide, sotalol hydrochloride) drugs significantly reduced recurrence of atrial fibrillation (number needed to treat, 2-9), but all increased withdrawals due to adverse effects (number needed to harm [NNH], 9-27) and all but amiodarone and propafenone increased proarrhythmia (NNH, 17-119). Class IA drugs, pooled, were associated with increased mortality compared with controls (Peto odds ratio, 2.39; 95% confidence interval, 1.03-5.59; P = .04; NNH, 109). No other antiarrhythmic showed a significant effect on mortality compared with controls. We could not analyze other outcomes because data were lacking. CONCLUSION: Class IA, IC, and III drugs are effective in maintaining sinus rhythm but increase adverse effects, and class IA drugs may increase mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 945
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
Flaker, G. C., Blackshear, J. L., McBride, R., Kronmal, R. A., Halperin, J. L., & Hart, R. G. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90003-6 · Cited by 632
Wattigney, W. A., Mensah, G. A., & Croft, J. B. (2003) · Circulation · doi:10.1161/01.cir.0000083722.42033.0a · Cited by 505
Pedersen, O. D., Bagger, H., Keller, N., Marchant, B., Køber, L., & Torp-Pedersen, C. (2001) · Circulation · doi:10.1161/01.cir.104.3.292 · Cited by 496
Outpatient treatment of recent-onset atrial fibrillation with the “Pill-in-the-Pocket” approach
Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041233 · Cited by 479
Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., & Billing, C. B. (2000) · Circulation · doi:10.1161/01.cir.102.19.2385 · Cited by 433
Juul-Möller, S., Edvardsson, N., & Rehnqvist-Ahlberg, N. (1990) · Circulation · doi:10.1161/01.cir.82.6.1932 · Cited by 341
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
FETSCH, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.015 · Cited by 334
Dronedarone for prevention of atrial fibrillation: A dose-ranging study
Touboul, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00321-x · Cited by 315
Maintenance of sinus rhythm in patients with atrial fibrillation
(2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00559-x · Cited by 281
Kühlkamp, V., Schirdewan, A., Stangl, K., Homberg, M., Ploch, M., & Beck, O. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00693-8 · Cited by 256
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
Reimold, S. C., Cantillon, C. O., Friedman, P. L., & Antman, E. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90511-a · Cited by 253
Rate vs Rhythm Control in Patients With Atrial Fibrillation: A Meta-analysis
de Denus, S. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.258 · Cited by 239
Hohnloser, S. H., van de Loo, A., & Baedeker, F. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00286-5 · Cited by 204
Van Gelder, I. C., Crijns, H. J. G. M., Van Gilst, W. H., Van Wijk, L. M., Hamer, H. P. M., & Lie, K. I. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90574-2 · Cited by 187
Page, R. L., Tilsch, T. W., Connolly, S. J., Schnell, D. J., Marcello, S. R., Wilkinson, W. E., & Pritchett, E. L. C. (2003) · Circulation · doi:10.1161/01.cir.0000051455.44919.73 · Cited by 166
Benditt, D. G., Williams, J. H., Jin, J., Deering, T. F., Zucker, R., Browne, K., Chang-Sing, P., & Singh, B. N. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00275-1 · Cited by 165
Suppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial
PATTEN, M., MAAS, R., BAUER, P., LUDERITZ, B., SONNTAG, F., DLUZNIEWSKI, M., HATALA, R., OPOLSKI, G., MULLER, H., & MEINERTZ, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.014 · Cited by 157
Södermark, T., Jönsson, B., Olsson, A. G., Orö, L., Wallin, H., Edhag, O., Sjögren, A., Danielsson, M., & Rosenhamer, G. (1975) · Heart · doi:10.1136/hrt.37.5.486 · Cited by 142
Karlson, B. W., Torstensson, I., Abjörn, C., Jansson, S.-O., & PETERSON|, L. E. (1988) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a062498 · Cited by 137
Naccarelli, G. V., Dorian, P., Hohnloser, S. H., & Coumel, P. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89118-7 · Cited by 134
Nichol, G., McAlister, F. A., Pham, B., Laupacis, A., Shea, B., Green, M. S., Tang, A., & Wells, G. (2002) · Heart · doi:10.1136/heart.87.6.535 · Cited by 123
Propafenone for Conversion and Prophylaxis of Atrial Fibrillation
Stroobandt, R., Stiels, B., & Hoebrechts, R. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00779-5 · Cited by 118
Plewan, A., Lehmann, G., Ndrepepa, G., Schreieck, J., Alt, E. U., Schömig, A., & Schmitt, C. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2546 · Cited by 110
Pritchett, E. L. C., Page, R. L., Carlson, M. D., Undesser, K. P., & Fava, G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00974-3 · Cited by 105
Hillestad, L., Bjerkelund, C. J., Dale, J., Maltau, J. M., & Storstein, O. (1971) · Heart · doi:10.1136/hrt.33.4.518 · Cited by 98
Allot, E., & Denjoy, I. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89120-5 · Cited by 98
KOCHIADAKIS, G. E., Igoumenidis, N. E., Marketou, M. E., Kaleboubas, M. D., Simantirakis, E. N., & Vardas, P. E. (2000) · Heart · doi:10.1136/heart.84.3.251 · Cited by 97
Amiodarone versus quinidine in the prophylaxis of atrial fibrillation.
Vitolo, E., Tronci, M., Larovere, M. T., Rumolo, R., & Morabito, A. (1981) · PubMed · Cited by 97
Waldo, A. L. (2006) · Yearbook of Cardiology · doi:10.1016/s0145-4145(07)70267-8 · Cited by 96
Golzari, H., Cebul, R. D., & Bahler, R. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-4-199608150-00010 · Cited by 92
Miller, M. R., McNamara, R. L., Segal, J. B., Kim, N. H., Robinson, K. A., Goodman, S. N., Powe, N. R., & Bass, E. B. (2000) · PubMed · Cited by 91
Byrne-Quinn, E., & Wing, A. J. (1970) · Heart · doi:10.1136/hrt.32.3.370 · Cited by 89
Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation
Singh, S., Saini, R. K., Dimarco, J., Kluger, J., Gold, R. L., & Chen, Y. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90200-5 · Cited by 85
Bellandi, F., Simonetti, I., Leoncini, M., Frascarelli, F., Giovannini, T., Maioli, M., & Dabizzi, R. P. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01806-9 · Cited by 83
Crijns, H. J. G. M., Gosselink, A. T. M., & Lie, K. I. (1996) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00823592 · Cited by 82
Channer, K. S. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.10.020 · Cited by 81
CHIMIENTI, M., The Flecainide and Propafenone Italian Study (FAPIS) Investigators, Cullen, M. T., & Casadei, G. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89119-9 · Cited by 78
Galperín, J., Elizari, M. V., Chiale, P. A., Molina, R. T., Ledesma, R., Scapín, A. O., & Blanco, M. V. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600403 · Cited by 68
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide
Zarembski, D. G. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.17.1885 · Cited by 66
Lloyd, E. A., Bj, G., & Forman, R. (1984) · PubMed · Cited by 60
KOCHIADAKIS, G. E., Igoumenidis, N. E., Hamilos, M. I., Tzerakis, P. G., Klapsinos, N. C., Zacharis, E. A., & Vardas, P. E. (2004) · CHEST Journal · doi:10.1378/chest.125.2.377 · Cited by 45
Wattigney, W. A., Mensah, G. A., & Croft, J. B. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.10.016 · Cited by 42
de Paola, Â. A. V., & Veloso, H. H. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00494-4 · Cited by 41
KOCHIADAKIS, G. E., Igoumenidis, N. E., Hamilos, M. E., Tzerakis, P. G., Klapsinos, N. C., CHLOUVERAKIS, G. I., & Vardas, P. E. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.041 · Cited by 31
Okishige, K., Nishizaki, M., Azegami, K., Igawa, M., Yamawaki, N., & Aonuma, K. (2000) · American Heart Journal · doi:10.1067/mhj.2000.107174 · Cited by 31
Doğan, A., Ergene, O., Nazlı, C., Kınay, O., Altınbaş, A., Ucarci, Y., Ergene, Ü., Özaydın, M., & Gedikli, Ö. (2004) · Acta Cardiologica · doi:10.2143/ac.59.3.2005179 · Cited by 31
Dahlin, J., Svendsen, P., & Gadsbøll, N. (2003) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430310016090 · Cited by 24
Rate vs. Rhythm Control in Patients With Atrial Fibrillation. A Meta-Analysis
de Denus, S., Sanoski, C. A., CARLSSON, J., Opolski, G., & Spinler, S. A. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.05.063 · Cited by 23
Atarashi, H., Inoue, H., Fukunami, M., et al. (2002) · Circulation Journal · doi:10.1253/circj.66.553 · Cited by 23
Spontaneous conversion to sinus rhythm of recent (within 24 hours) atrial fibrillation.
Geleris, P., Stavrati, A., Afthonidis, D., Kirpizidis, H. G., & Boudoulas, H. (2001) · PubMed · Cited by 23
Steinbeck, G., Doliwa, R., & Bach, P. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1067903 · Cited by 18
Treatment of Atrial Fibrillation and Paroxysmal Supraventricular Tachycardia With Bidisomide
(1997) · Circulation · doi:10.1161/01.cir.96.8.2625 · Cited by 17
Carunchio, A., Fera, M. S., Mazza, A., Burattini, M., Greco, G., Galati, A., & Ceci, V. (1995) · PubMed · Cited by 17
Kalusche, D., Stockinger, J., Betz, P., & Roskamm, H. (1994) · PubMed · Cited by 15
Cited by
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Potentially inappropriate medications in the elderly: a French consensus panel list
Laroche, M.-L., Charmes, J.-P., & Merle, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0324-2 · Cited by 517
Metadata
- Authors
- Lafuente-Lafuente, C., Mouly, S., Longás-Tejero, M. A., Mahé, I., & Bergmann, J.-F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2006-04-10
- Volume
- 166
- Issue
- 7
- Pages
- 719
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2107934559
- Cited by
- 288
- References
- 61
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.